PA
CHRS icon

Perceptive Advisors’s Coherus Oncology CHRS Stock Holding History

Perceptive Advisors’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,667,123
Closed -$16M – 100
2022
Q3 		$16M Sell
1,667,123
-1,978,348
-54% -$20M 0.47% 52
2022
Q2 		$26.4M Sell
3,645,471
-1,050,377
-22% -$9.13M 0.83% 28
2022
Q1 		$60.6M Sell
4,695,848
-711,950
-13% -$9.05M 1.21% 22
2021
Q4 		$86.3M Buy
5,407,798
+628,411
+13% +$11M 1.33% 20
2021
Q3 		$76.8M Buy
4,779,387
+81,775
+2% +$1.2M 1.12% 25
2021
Q2 		$65M Hold
4,697,612
– – 0.84% 33
2021
Q1 		$68.6M Buy
4,697,612
+25,776
+0.6% +$438K 0.87% 30
2020
Q4 		$81.2M Buy
4,671,836
+1,035,351
+28% +$18.4M 0.87% 34
2020
Q3 		$66.7M Buy
3,636,485
+3,091,200
+567% +$57.5M 0.97% 25
2020
Q2 		$9.74M Buy
+545,285
New +$9.23M 0.16% 82
2015
Q3 		– Sell
-258,716
Closed -$7.48M – 160
2015
Q2 		$7.48M Buy
258,716
+173,428
+203% +$4.38M 0.45% 50
2015
Q1 		$2.61M Sell
85,288
-352,712
-81% -$9.12M 0.2% 78
2014
Q4 		$7.15M Buy
+438,000
New +$6.18M 0.6% 42

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Perceptive Advisors's CHRS Position: Q4 2022 in Review

Perceptive Advisors sold out of Coherus Oncology (CHRS) in Q4 2022, closing a stake of 1,667,123 shares — an estimated $16M sold.

Perceptive Advisors first reported a position in CHRS in Q4 2014 and held it in 13 quarters. The position peaked at $86.3M in Q4 2021. 161 funds tracked by Wall St. Rank hold CHRS as of Q4 2022.

  • Perceptive Advisors reported no remaining Coherus Oncology position as of Q4 2022 after selling out during the quarter.
  • Perceptive Advisors sold 1,667,123 Coherus Oncology shares in Q4 2022, an estimated $16M.
  • Perceptive Advisors first reported a position in Coherus Oncology in Q4 2014 and held it in 13 quarters.
  • Perceptive Advisors's Coherus Oncology position peaked at $86.3M in Q4 2021.
  • 161 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2022.

Based on Perceptive Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.